$13,299.27 speaking Payment -- Johnson & Johnson to Dr. Robert Johnson
General Surgeon Earned Over $13,000 for Johnson & Johnson Speaking Engagement
This page provides a detailed analysis of a $13,299.27 speaking payment from Johnson & Johnson to Dr. Robert Johnson. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $13,299.27 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Johnson & Johnson |
| Physician | Dr. Robert Johnson |
| NPI Number | 1286278442 |
| Physician Specialty | General Surgery |
| Location | San Antonio, TX |
| Date of Payment | 2024-05-31 |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Johnson & Johnson made a $13.3K speaking payment to Robert Johnson, a General Surgery specialist in San Antonio, TX. Dr. Robert Johnson received $13,299.27 from Johnson & Johnson for speaking engagements in May 2024. The payment was for serving as faculty or a speaker, indicating an educational or informational role. This payment represents a significant amount for a single speaking engagement, potentially influencing prescribing habits.
Patient Guidance: What This Payment Means for You
If you see your doctor receiving payments from pharmaceutical companies for speaking, it's important to understand that these payments are intended to compensate for educational services, but it's always wise to discuss all treatment options and potential conflicts of interest. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
While speaking fees are common in many specialties, the amount of $13,299.27 for a single engagement in General Surgery may be higher than average and warrants consideration of potential influence.
Regulatory Context: Sunshine Act Requirements
Payments to physicians for speaking engagements are reportable under the Sunshine Act, requiring disclosure to ensure transparency in the relationship between healthcare providers and the pharmaceutical industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-fees
- physician-payments
- pharma-industry
- johnson-johnson
- general-surgery
- open-payments
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $13.3K payment for?
This was a speaking payment of $13.3K from Johnson & Johnson to Robert Johnson, categorized as "Compensation for serving as faculty or as a speaker". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Robert Johnson accept pharmaceutical money?
Yes, Robert Johnson received this $13.3K payment from Johnson & Johnson. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Robert Johnson's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $13.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in General Surgery?
To compare this payment against General Surgery averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. General Surgery physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Robert Johnson's relationship with Johnson & Johnson?
The payment amount is substantial for a speaking role. This $13.3K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for General Surgery?
The payment was made directly to the physician, not through an intermediary.
What should patients do after learning about this payment?
If you see your doctor receiving payments from pharmaceutical companies for speaking, it's important to understand that these payments are intended to compensate for educational services, but it's always wise to discuss all treatment options and potential conflicts of interest.
What else should I know about this speaking payment?
The date of payment is recent, falling within the current reporting period.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.